The field of rhinology and allergy is constantly evolving, which is reflected in this edition of The American Journal of Rhinology and Allergy (AJRA). The September 2019 issue features articles on a wide variety of subjects including the examination of endotypes and phenotypes of chronic rhinosinusitis (CRS) and rhinitis, novel mechanisms of inflammation and fibrosis in polyps, and deeper insights into the foundations of medical and surgical treatment for these conditions. AJRA continues to select a breadth of articles from authors across the world in basic science and clinical research that can further the knowledge and practice of a wide variety of readers including otolaryngologists, allergists, immunologists, and scientists.
Several articles in this issue examine methods to better characterize CRS and rhinitis phenotypes in order to improve management of these diseases. Radabaugh et al. found that clinical diagnosis of comorbid bronchial asthma or allergic rhinitis (AR) in CRS patients correlated with increased tissue eosinophil ratios on biopsy, indicating we may be able to use these clinical features rather than invasive testing to characterize CRS histopathologic endotypes. 1 The contribution of AR to the pathogenesis of CRS is not clear. Anamika et al. examined the effect of comorbid AR in children with CRS and found that those with AR had increased disease severity in terms of Lund Mackay endoscopic score and worse quality of life. 2 In current clinical practice, it can be very difficult to make the diagnosis of local AR versus non-AR. Phothijindakul et al. found nasal cytology examination for nasal eosinophilia to be a useful screening tool with high sensitivity for diagnosing local AR. 3 Hamizan et al. found that patients who were older, lacked comorbid asthma, and did not have self-reported inhalant allergy triggers were more likely to be diagnosed with true non-AR. 4 Another article from Hwang et al. examined bisphosphonate use and chronic osteitis as a unique pathogenic factor for CRS. 5 This issue delves into the evidence behind some of our mainstay treatments for CRS and AR and their safety and effectiveness. Zhang et al. reviewed the use of a short course of systemic corticosteroids in the treatment of CRS with nasal polyps. 6 In comparison to placebo or nonsteroid treatments, patients treated with systemic corticosteroids had significant improvements in outcomes including nasal obstruction scores, nasal polyp size, and peak nasal inspiratory flow. They also importantly noted that the efficacy was similar between highand low-dose steroid groups, while those in high-dose groups had significantly more side effects including insomnia and gastrointestinal disturbances, arguing for use of low-dose regimen rather than high-dose regimen. Deot et al. reviewed the effect of intranasal corticosteroids, aqueous versus nonaqueous formulations, on secondary sinonasal symptoms including cough, postnasal drip, facial pain/pressure, headache, and ear fullness. 7 Although in theory, nonaqueous formulations should have better drug delivery to more distal regions of the nasal cavity, despite an extensive literature search, there was very limited data comparing aqueous to nonaqueous formulations, indicating this is an area that still requires further investigation. Another form of topical steroids, mometasone furoate sinus implants, provided significant improvements in outcomes including nasal obstruction/ congestion score, bilateral polyp grade, and ethmoid sinus obstruction and potentially less need for surgical revision compared to mometasone furoate nasal spray in patients with CRS with nasal polyps. 8 In a systematic review and meta-analysis from Seresirikachorn et al., the combination of leukotriene receptor antagonist plus antihistamine compared to antihistamine alone was more effective in improving nasal symptom score, rhinorrhea, and sneezing in patients with perennial AR. 9 In addition, the authors in this issue of AJRA continue to expand our knowledge in terms of surgical techniques and improving outcomes after surgical intervention. There are no current guidelines established on surgical management of frontal sinus osteoma. Watley et al. performed a systematic review of the literature and compared open approach versus endoscopic or combined resection and also was able to develop a novel Frontal Sinus Osteoma Grading System to assist surgeons in choosing the ideal approach. 10 Surgical resection of sinonasal malignancies is often challenging and complex due to anatomy and close proximity of critical neurovascular structures. Lu et al. compared open resection versus endoscopic resection approach for sinonasal malignancies in the largest direct comparison to date and found significantly shorter length of stay for endoscopic resection, but no significant difference in risk of unfavorable outcomes between the two, despite the widely held belief that endoscopic resection would have lower complication rates. 11 Neither treatment with higher concentration topical dexamethasone nasal steroid spray nor absorbable hemostatic packing improved postsurgical outcomes in patients after functional endoscopic sinus surgery, indicating these interventions are not likely to be useful to apply to all postsurgical patients. 12, 13 Several articles in the issue address potential future treatment options by examining mechanisms of inflammation that are pathogenic in CRS. Acacia honey, which is thought to have antioxidant, immune-modulatory, and antiproliferative properties, was found to inhibit transforming growth factor-beta-1 (TGF-b1)-induced myofibroblast differentiation and metalloproteinase-9 (MMP-9) production in nasal fibroblasts, which potentially could prevent nasal polyp formation.
14 Another study by Li et al. looked at relaxin-2, a small peptide hormone that modulates extracellular matrix remodeling and decreases fibrosis. 15 In tissue from patients with CRS with nasal polyps in in vitro experiments, relaxin-2 appeared to inhibit fibrosis, probably by regulating the overexpression of TGF-b1. Besides fibrosis, we also know that Staphylococcus aureus has been shown to be a significant factor in the pathogenesis of CRS, leading to barrier dysfunction and production of toxins. Kaya et al. inoculated rats' nasal cavities with S. aureus and then treated with montelukast, a leukotriene-receptor antagonist. 16 They found that the inflammatory reaction, including cytokines tumor necrosis factor-a and interleukin-1a, was reduced in those that were treated with montelukast, both alone or in combination with cefazolin. In addition, Suzuki et al. found that the administration of CD86-or CD40-/CD86-silenced ovalbumin-pulsed B cells decreased allergic responses in mice, which may be useful in development of novel vaccine therapy or treatment of allergic diseases. 17 Finally, the authors also address the important role that psychosocial factors play in management of patients presenting to clinic. Alam et al. found high rates of somatization symptoms in patients presenting to a specialty rhinology clinic, especially in females and in patients presenting with headache or nasal discharge. 18 This comorbidity is especially important to address, as there is known to be higher health-care utilization and costs in patients with somatic symptom disorder. Tait et al. developed and evaluated the validity of the 25-item Sino-Nasal Outcome Test (SNOT-25), a modified version of SNOT-22, to assess rhinosinusitis disease burden, including new items that address the impact on productivity losses attributed to the disease. 19 In summary, the September 2019 issue of AJRA covers a wide range of topics from authors around the world that further our understanding of the pathogenesis and management of patients in the rhinology practice. The articles range from those that deepen our knowledge of current treatments and practices, to those that examine new inflammatory mechanisms and potential future directions of study. The editors and reviewers at AJRA continue to select high impact articles that further the field of rhinology. I hope that you find the contents of this issue to offer unique and innovative perspectives in the field relevant to your clinical and academic practice.
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